Provided by Tiger Trade Technology Pte. Ltd.

Cogent Biosciences, Inc.

37.81
-1.0800-2.78%
Volume:904.32K
Turnover:33.65M
Market Cap:6.14B
PE:-17.50
High:38.08
Open:37.39
Low:36.40
Close:38.89
52wk High:43.73
52wk Low:3.72
Shares:162.31M
Float Shares:143.00M
Volume Ratio:0.63
T/O Rate:0.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1600
EPS(LYR):-2.5504
ROE:-73.70%
ROA:-32.93%
PB:11.22
PE(LYR):-14.83

Loading ...

Cogent Biosciences reicht Zulassungsantrag für Bezuclastinib bei der FDA ein

Reuters
·
Feb 10

U.S. RESEARCH ROUNDUP-KKR, Sirius XM, Workday

Reuters
·
Feb 10

Assessing Cogent Biosciences (COGT) Valuation After FDA Breakthrough Therapy And Real Time Oncology Review News

Simply Wall St.
·
Feb 05

13D Filings -- Barrons.com

Dow Jones
·
Jan 31

Raymond James Reaffirms Their Buy Rating on Cogent Biosciences (COGT)

TIPRANKS
·
Jan 27

FDA Grants Breakthrough Therapy Designation to Cogent Biosciences' Bezuclastinib Combination for GIST

Reuters
·
Jan 26

Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination With Sunitinib for Patients With Gastrointestinal Stromal Tumors (Gist)

THOMSON REUTERS
·
Jan 26

Cogent Biosciences Inc - on Track to Complete Nda Submission in April 2026

THOMSON REUTERS
·
Jan 26

Fairmount Funds Management LLC Reports Disposal of Cogent Biosciences Inc. Common Shares

Reuters
·
Jan 23

FDA Accepts NDA for Cogent Biosciences' Bezuclastinib Combination in GIST Under RTOR Program

Reuters
·
Jan 20

Cogent Biosciences to Initiate New Drug Application (Nda) Submission for Bezuclastinib Under Real-Time Oncology Review (Rtor)

THOMSON REUTERS
·
Jan 20

Cogent Biosciences Inc - to Initiate Rtor Process, Completion of Peak Nda Submission by April 2026

THOMSON REUTERS
·
Jan 20

Cogent Biosciences (COGT) Gets a Buy from Wedbush

TIPRANKS
·
Jan 13

Raymond James Sticks to Its Buy Rating for Cogent Biosciences (COGT)

TIPRANKS
·
Jan 13

Cogent Biosciences Grants Equity Awards to New Employees Under 2020 Inducement Plan

Reuters
·
Jan 12

Does Cogent Biosciences (COGT) Bezuclastinib NDA Redefine Its Competitive Position in Mastocytosis Treatment?

Simply Wall St.
·
Jan 07

BRIEF-Cogent Biosciences Announces Presentation At The 44Th Annual J.P. Morgan Healthcare Conference

Reuters
·
Jan 06

Cogent Biosciences Chief Scientific Officer John Robinson Sells 50% Of Holding

Simply Wall St.
·
Jan 02

Cogent Biosciences Chief Scientific Officer John Edward Robinson Reports Disposal of Common Shares

Reuters
·
Dec 31, 2025

Cogent Biosciences Submits NDA to FDA for Bezuclastinib in NonAdvanced Systemic Mastocytosis

Reuters
·
Dec 30, 2025